No connection

Search Results

ICUI vs SUPN

ICUI
ICU Medical, Inc.
BEARISH
Price
$125.68
Market Cap
$3.14B
Sector
Healthcare
AI Confidence
80%
SUPN
Supernus Pharmaceuticals, Inc.
NEUTRAL
Price
$51.39
Market Cap
$2.96B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ICUI
4189.33
SUPN
--
Forward P/E
ICUI
13.66
SUPN
12.18
P/B Ratio
ICUI
1.46
SUPN
2.78
P/S Ratio
ICUI
1.41
SUPN
4.12
EV/EBITDA
ICUI
13.35
SUPN
60.62

Profitability

Gross Margin
ICUI
36.84%
SUPN
89.63%
Operating Margin
ICUI
4.83%
SUPN
-28.9%
Profit Margin
ICUI
0.03%
SUPN
-5.36%
ROE
ICUI
0.04%
SUPN
-3.68%
ROA
ICUI
1.66%
SUPN
-2.09%

Growth

Revenue Growth
ICUI
-14.1%
SUPN
21.5%
Earnings Growth
ICUI
--
SUPN
--

Financial Health

Debt/Equity
ICUI
0.63
SUPN
0.04
Current Ratio
ICUI
2.39
SUPN
1.91
Quick Ratio
ICUI
0.99
SUPN
1.47

Dividends

Dividend Yield
ICUI
--
SUPN
--
Payout Ratio
ICUI
0.0%
SUPN
0.0%

AI Verdict

ICUI BEARISH

ICUI presents a stark contradiction between a strong balance sheet and a collapsing income statement. While the Piotroski F-Score of 8/9 indicates exceptional structural financial health, the company is suffering from a severe earnings crisis, evidenced by a P/E ratio of 4189.33 and a -131.5% Q/Q EPS growth. The massive disconnect between the current price ($125.68) and the Graham Number ($7.62) suggests the stock is trading at a significant premium based on future recovery hopes rather than current fundamentals. With revenue declining by 14.1% and insiders selling, the strong health score is currently insufficient to offset the operational deterioration.

Strengths
Strong Piotroski F-Score (8/9) indicating high structural health
Healthy Current Ratio (2.39) showing strong short-term liquidity
Manageable Debt/Equity ratio (0.63)
Risks
Severe earnings collapse with recent Q/Q EPS growth of -131.5%
Negative revenue growth (-14.10% YoY) indicating market share loss or demand drop
Extreme valuation disconnect (Current P/E 4189.33 vs Forward P/E 13.66)
SUPN NEUTRAL

SUPN presents a contradictory profile, characterized by a weak Piotroski F-Score of 2/9 and bearish insider sentiment (30/100). Despite these fundamental warnings, the company shows strong top-line growth (21.5% YoY) and maintains a very low debt-to-equity ratio of 0.04. Analysts remain highly optimistic with a 'Strong Buy' consensus and a target price of $63.17, suggesting a disconnect between current operational health and future growth expectations. The stock is currently a speculative play where strong revenue growth is fighting against deteriorating fundamental health metrics.

Strengths
Strong revenue growth of 21.50% YoY
Very low leverage with a Debt/Equity ratio of 0.04
High Gross Margin of 89.63%
Risks
Weak fundamental health indicated by a Piotroski F-Score of 2/9
Negative operating margins (-28.90%) indicating inefficiency
Heavy insider selling totaling $9.00M in the last 6 months

Compare Another Pair

ICUI vs SUPN: Head-to-Head Comparison

This page compares ICU Medical, Inc. (ICUI) and Supernus Pharmaceuticals, Inc. (SUPN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile